loading...| Preferred Name |
golimumab |
|
| Synonyms |
CNTO 148 immunoglobulin G1, anti-(human Tumor Necrosis Factor Alpha) (human monoclonal CNTO 148 gamma-1-chain), disulfide with human monoclonal CNTO 148 kappa-chain, dimer |
|
| Definitions |
A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. Golimumab binds to TNF-a, thereby preventing TNF-a-mediated immune responses. TNF-a production is dysregulated in various auto-immune diseases and in cancer. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87766" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87766" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000791699 |
|
| altLabel |
CNTO 148 immunoglobulin G1, anti-(human Tumor Necrosis Factor Alpha) (human monoclonal CNTO 148 gamma-1-chain), disulfide with human monoclonal CNTO 148 kappa-chain, dimer |
|
| CAS Registry |
476181-74-5 |
|
| cui |
C2353893 C2987601 |
|
| DATE FIRST PUBLISHED |
2017-12-22 |
|
| Date last modified |
2017-12-21 |
|
| definition |
A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. Golimumab binds to TNF-a, thereby preventing TNF-a-mediated immune responses. TNF-a production is dysregulated in various auto-immune diseases and in cancer. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87766" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87766" NCI Thesaurus) |
|
| NCI ID |
C87766 |
|
| notation |
CDR0000791699 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
golimumab |
|
| tui |
T116 T129 T121 |